The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03255070




Registration number
NCT03255070
Ethics application status
Date submitted
14/08/2017
Date registered
16/08/2017
Date last updated
12/03/2018

Titles & IDs
Public title
A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
Scientific title
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression
Secondary ID [1] 0 0
ARX788-1711
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Neoplasms 0 0
Stomach Neoplasm 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast
Cancer 0 0 0 0
Stomach

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ARX788

Experimental: Phase 1a: Cohort 1 - Cohort 1 will administer Dose Level 1 of ARX788 every 4 weeks (Q4W) via intravenous infusion.

Experimental: Phase 1a: Cohort 2 - Cohort 1 will administer Dose Level 1 of ARX788 every 3 weeks (Q3W) via intravenous infusion.

Experimental: Phase 1a: Cohort 3 - Cohort 3 will administer Dose Level 2 of ARX788 every 4 weeks (Q4W) via intravenous infusion.

Experimental: Phase 1a: Cohort 4 - Cohort 4 will administer Dose Level 2 of ARX788 every 3 weeks (Q3W) via intravenous infusion.

Experimental: Phase 1a: Optional Cohort 5 Q3W - Cohort 5 may administer Dose Level 3 of ARX788 every 3 weeks (Q3W) via intravenous infusion.


Treatment: Drugs: ARX788
An antibody drug conjugate

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of subjects experiencing adverse events, frequency and seriousness of treatment emergent adverse events (TEAEs)
Timepoint [1] 0 0
Day 1 through 30 days after last dose
Primary outcome [2] 0 0
Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1. - Number of subjects with objective response is assessed every 6-8 weeks from Cycle 1 Day 1 through disease progression.
Timepoint [2] 0 0
18 months
Secondary outcome [1] 0 0
Number of subjects with tumor response per imaging assessment based on RECIST version 1.1.
Timepoint [1] 0 0
18 months
Secondary outcome [2] 0 0
Area under the concentration-time curve (AUC) from first infusion to subject end of study. - Pharmacokinetic (PK) characteristics: ARX788 (intact ADC), total mAb, and metabolites
Timepoint [2] 0 0
18 months
Secondary outcome [3] 0 0
Half-life of ARX788 from first infusion to end of study. - Pharmacokinetic (PK) characteristics: ARX788 from first infusion to subject end of study
Timepoint [3] 0 0
18 months
Secondary outcome [4] 0 0
Immunogenicity profile of ARX788 - Number of subjects who develop anti-ARX788 antibody
Timepoint [4] 0 0
18 months

Eligibility
Key inclusion criteria
- Age >18 years and =75 years.

- Life expectancy >12 weeks.

- BMI 18 to 32 kg/m2.

- Female or male subjects whose advanced HER2 expressing cancer has failed standard of
care treatments, or for whom such therapy is not acceptable to the subject. Subjects
with advanced breast and gastric cancer who test positive for HER2 by ASCO/CAP
criteria (either IHC or FISH) must have received prior treatment with a trastuzumab
containing therapy. Subjects who have been previously treated with pertuzumab, TDM-1,
lapatinib, or other available and accessible HER2-directed therapies or
investigational therapies are eligible.

- Disease measurability:

- Phase 1a: measurable or non-measurable disease per RECIST v 1.1.

- Phase 1b: measurable disease per RECIST v 1.1 (subjects with non-measurable
disease are not eligible for Phase 1b).

- Histopathologic evidence of cancer based upon pathologist's report.

- Tumor tissue local laboratory HER2 testing results (clinical pathology report) based
on FDA or other regulatory agency approved, validated or commercially available IHC or
ISH HER2 assay. Pre-screening for HER2 is allowed only for subjects with breast and
gastric cancer, GE junction or esophageal cancer, where applicable. Subjects with
other types of cancer must have previously tested for HER2 status by HER2 IHC or ISH
assay.

- Phase 1a: ISH positive or IHC 3+ advanced cancer (including breast or
gastric/esophageal or other solid tumors).

- Phase 1b:

- Cohort 1: advanced breast cancer, ISH positive or IHC 3+.

- Cohort 2: advanced breast cancer, ISH negative with IHC 2+.

- Eastern Cooperative Oncology Group Performance Status of 0 to 1.

- Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved
to Grade 0 or 1 as per the NCI-CTCAE v 4.03.

- Adequate renal function assessed by serum creatinine within reference lab normal
limits and creatinine clearance (by Chronic Kidney Disease Epidemiology [CKD-EPI]
Collaboration equation) =60 mL/min.

- Adequate cardiac function as assessed by cardiac troponin I within normal range; left
ventricular ejection fraction = 50% or institutional lower limit of normal; cumulative
anthracycline dose <360 mg/m2 doxorubicin or equivalent.

- Willing and able to understand and sign an informed consent inform and to comply with
all aspects of the protocol.

- Female subjects must be surgically sterile, or have a monogamous partner who is
surgically sterile, or at least 2 years postmenopausal, or who commits to use an
acceptable form of birth control (defined as the use of an intrauterine device, a
barrier method with spermicide, condoms, any form of hormonal contraceptives, or
abstinence) for the duration of the study and for 3 months following the last dose of
study treatment.

- Male subjects must be sterile (biologically or surgically) or commit to the use of a
reliable method of birth control (condoms with spermicide) for the duration of the
study.
Minimum age
18 Years
Maximum age
75 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of allergic reactions to any component of the IMP.

- History of interstitial lung disease, pneumonitis or other clinically significant lung
diseases.

- Any CT imaging findings indicating radiation or drug-induced lung disorders at the
time of screening

- Any known clinically significant prior radiation to the chest area that included lung
parenchyma.

- History of ocular events related to keratitis or corneal disorders, or any current
ongoing active ocular infections.

- History of seizure disorder.

- History of unstable central nervous system (CNS) metastases or seizure disorder
related to the malignancy; however, those subjects who were treated for prior CNS
metastases and who are asymptomatic may participate in the study as long as they are
not receiving treatment with steroids.

- History of congestive heart failure, unstable angina pectoris, unstable atrial
fibrillation, or cardiac arrhythmia.

- Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 4.03).

- Non-manageable electrolyte imbalances including hypokalemia, hypocalcemia, or
hypomagnesemia (Grade 2 or greater based on NCI-CTCAE v 4.03).

- Any uncontrollable intercurrent illness, infection, or other conditions that could
limit study compliance or interfere with assessments.

- Exposure to any other investigational or commercial anticancer agents or therapies
administered with the intention to treat malignancy within 28 days before the first
dose of the IMP. Hormonal therapy may be administered up to 7 days prior to the first
dose of the IMP.

- Clinically significant surgical intervention within 21 days of the first dose of the
IMP or with ongoing post-operative complications if more than 21 days.

- Radiotherapy administered less than 21 days prior to the first dose of the IMP, or
localized palliative radiotherapy administered less than 7 days prior to the first
dose of the IMP, or radiotherapy-induced toxicity of Grade 2 or greater based on
NCI-CTCAE v 4.03.

- Pregnancy or breast feeding.

- Refusal to use effective methods of contraception (see inclusion criteria for
details).

- Legal incapacity/limited legal capacity for providing informed consent.

- Known active HCV, HBV, and/or HIV infection.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Mater Misericordiae Limited - South Brisbane
Recruitment hospital [2] 0 0
Monash Health - Clayton
Recruitment postcode(s) [1] 0 0
4101 - South Brisbane
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Missouri

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Ambrx, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a 2-part, Phase 1, open-label study. Phase 1a of this study is designed to determine
the recommended Phase 2 dose (RP2D) in subjects with advanced cancer whose HER2 test results
are in situ hybridization (ISH) positive or immunohistochemistry (IHC) 3+ and Phase 1b is
designed to assess anticancer activity and safety in 2 advanced breast cancer expansion
cohorts: 1) for tumors that test as HER2 ISH positive or IHC3+ and, 2) for tumors that test
as HER2 ISH negative with IHC 2+.
Trial website
https://clinicaltrials.gov/show/NCT03255070
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Yong Jiang Hei, MD, PhD
Address 0 0
Country 0 0
Phone 0 0
858-875-2400
Fax 0 0
Email 0 0
yong.hei@ambrx.com
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Not applicable